EBS (STOCKS)
Emergent Biosolutions, Inc.
$7.944500
-0.015500 (-0.19%)
Prev close: $7.960000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joseph C. Papa
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $426.07M
- Employees
- 900
- P/E (TTM)
- 8.58
- P/B (TTM)
- 0.79
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
1
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.43 | $0.11 | -0.5411 | -487.04% |
|
Sep 2025 (Q3)
|
$1.06 | $-0.12 | +1.1812 | +974.59% |
|
Jun 2025 (Q2)
|
$0.16 | $-0.49 | +0.6549 | +132.33% |
|
Mar 2025 (Q1)
|
$0.71 | $0.44 | +0.2656 | +59.77% |
Financial Statements
| Revenues | $742.90M |
| Benefits Costs and Expenses | $660.10M |
| Cost Of Revenue | $326.20M |
| Costs And Expenses | $660.10M |
| Gross Profit | $416.70M |
| Nonoperating Income/Loss | -$17.30M |
| Operating Expenses | $316.60M |
| Selling, General, and Administrative Expenses | $186.10M |
| Research and Development | $53.20M |
| Other Operating Expenses | $77.30M |
| Operating Income/Loss | $100.10M |
| Income/Loss From Continuing Operations After Tax | $52.60M |
| Income/Loss From Continuing Operations Before Tax | $82.80M |
| Income Tax Expense/Benefit | $30.20M |
| Income Tax Expense/Benefit, Current | $34.10M |
| Income Tax Expense/Benefit, Deferred | -$3.90M |
| Net Income/Loss | $52.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $52.60M |
| Net Income/Loss Available To Common Stockholders, Basic | $52.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.98 |
| Diluted Earnings Per Share | $0.93 |
| Basic Average Shares | 53,500,000 |
| Diluted Average Shares | 56,700,000 |
| Assets | $1.32B |
| Current Assets | $662.50M |
| Inventory | $343.40M |
| Other Current Assets | $319.10M |
| Noncurrent Assets | $656.10M |
| Fixed Assets | $205.40M |
| Intangible Assets | $436.50M |
| Other Non-current Assets | $14.20M |
| Liabilities | $796.00M |
| Current Liabilities | $132.20M |
| Accounts Payable | $55.60M |
| Wages | $41.80M |
| Other Current Liabilities | $34.80M |
| Noncurrent Liabilities | $663.80M |
| Long-term Debt | $589.70M |
| Other Non-current Liabilities | $74.10M |
| Equity | $522.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $522.60M |
| Liabilities And Equity | $1.32B |
| Net Cash Flow From Operating Activities | $170.60M |
| Net Cash Flow From Operating Activities, Continuing | $170.60M |
| Net Cash Flow From Investing Activities | $69.40M |
| Net Cash Flow From Investing Activities, Continuing | $69.40M |
| Net Cash Flow From Financing Activities | -$136.60M |
| Net Cash Flow From Financing Activities, Continuing | -$136.60M |
| Exchange Gains/Losses | $100.00K |
| Net Cash Flow | $103.50M |
| Net Cash Flow, Continuing | $103.40M |
| Comprehensive Income/Loss | $50.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $50.30M |
| Other Comprehensive Income/Loss | $50.30M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.30M |